However, CBP-12 was able to deliver exogenous and endogenous tumor antigens to Clec9a and induced an antigen-specific antitumor response in the absence of an adjuvant, thus eliminating the risk of side effects associated with adjuvants. This evidence concerns the gene CLEC9A and neoplasm.